OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
  • PIPELINE
  • INVESTORS
  • NEWS
  • HOME
  • COMPANY
  • PIPELINE
  • INVESTORS
  • NEWS

Unlocking the Therapeutic Potential of Ketamine.

We are developing a patented, long-acting ketamine (KET-100) for neuropsychiatric disorders.

Corporate Presentation

November 2025

OTCQB: PHRRF | CSE: PHRM

Press Releases

View all press releases

Sign Up for Press Releases

SIGN UP

Contact Us

PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario, M5C 1P1
​
Canada
​Tel: 1-888-846-3171
Psychedelic Pharmaceuticals
Contact Us
© COPYRIGHT 2025.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."